Half-life
Component-dependent
Evidence Level
Moderate Evidence
Mechanism of Action
GHRH (CJC) and GHRP (Ipamorelin) act on different but synergistic pathways in the hypothalamic-pituitary axis, producing GH pulses greater than either alone (amplification effect).
Published Research Ranges & Study Context
Studies have administered: Typically 100–200mcg of each component per injection in research
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
GHRH+GHRP synergy well-documented in endocrinology literature. Combined peptides produce GH pulses 2–10x greater than either alone in some studies.
Moderate Evidence
Phase 1/2 human trials available
Side Effects Observed in Research
Consistent with individual components; water retention, injection site reactions
Available Configurations (SKU Reference)
CP10
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on CJC+Ipa Combo — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.